Skip to main content

Table 3 Characteristics of CTC-positive patients

From: Determination of the androgen receptor status of circulating tumour cells in metastatic breast cancer patients

PatientMenopausal statusIHC tumour typeNumber of previously received treatment linesaMetastatic siteCTC countAR positive CTC (%)AR localization
1postmenopausalHR+ HER2-1bone visceral10184 (83)cytoplasm/nucleus
2premenopausalHR+ HER2-0bone137 (54)cytoplasm
3postmenopausalHR+ HER2-2bone visceral103 (30)cytoplasm
4postmenopausalHR+
HER2-
2bone90 (0)
5premenopausalTNBC0bone visceral81 (12)cytoplasm
6premenopausalHR+ HER2-0bone77 (100)nucleus
7unknownHR+ HER2-0unknown43 (75)cytoplasm
8postmenopausalHR+ HER2-4bone visceral43 (75)cytoplasm
9postmenopausalHR+ HER2-0bone31 (33)cytoplasm
10postmenopausalHR+ HER2-7bone33 (100)cytoplasm
11postmenopausalHR+ HER2-0visceral33 (100)cytoplasm
12postmenopausalHR+ HER2-3bone visceral30 (0)
13postmenopausalHR+ HER2-4bone visceral30 (0)
14postmenopausalHR+ HER2-1bone visceral30 (0)
15unknownHR+ HER2+2visceral30 (0)
16premenopausalHR+ HER2-0bone lymph nodes30 (0)
17premenopausalTNBC1bone visceral21 (50)nucleus
18postmenopausalHR+ HER2-1bone20
19postmenopausalHR+ HER2-2bone visceral20
20postmenopausalHR+ HER2-2bone visceral20
21postmenopausalTNBC0visceral20
22postmenopausalHR+ HER2-2bone lymph nodes20
23postmenopausalHR+ HER2-2bone20
24postmenopausalHR+ HER2-1bone visceral20
25premenopausalHR+ HER2-0bone20
26postmenopausalHR+ HER2-1bone visceral11 (100)-nucleus
27postmenopausalHR+ HER2-0bone visceral11 (100)nucleus
28postmenopausalHR+ HER2-3bone visceral11 (100)cytoplasm
29postmenopausalHR+ HER2-0Lymph nodes11 (100)nucleus
30postmenopausalHR+ HER2-7Bone lymph nodes11 (100)cytoplasm
31postmenopausalHR+ HER2-0visceral10
32postmenopausalHR+ HER2-0bone visceral10
33premenopausalTNBC1visceral10
34postmenopausalHR+ HER2-0visceral10
35postmenopausalHR+ HER2-0visceral10
36postmenopausalTNBC1bone visceral10
37postmenopausalTNBC2visceral10
  1. afor metastatic disease